Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.7K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.7K
Dysrhythmias IV: Characteristics of Bradyarrhythmias01:18

Dysrhythmias IV: Characteristics of Bradyarrhythmias

664
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
664
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

3.8K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
3.8K
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

544
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
544
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

853
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
853
Dysrhythmias I: Introduction01:15

Dysrhythmias I: Introduction

689
Dysrhythmias refers to abnormalities in the heart's rhythm. They result from disruptions in the heart's electrical conduction system, which includes the sinoatrial(SA)node, atrioventricular(AV) node, the bundle of His, bundle branches, and Purkinje fibers.Definition and PathophysiologyDysrhythmias result from disorders of impulse formation, impulse conduction, or both. The heart contains specialized cells in the sinoatrial node, atrioventricular node, and the bundle of His and Purkinje fibers...
689

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mixed Epithelial and Stromal Tumor of the Kidney in a Patient With Mental Retardation: A Case Report.

IJU case reports·2025
Same author

Characteristics of Visual Cognition in Patients with Anoxic Encephalopathy: An Eye-tracking Study.

Progress in rehabilitation medicine·2024
Same author

Genome-wide association study of idiopathic hypersomnia in a Japanese population.

Sleep and biological rhythms·2024
Same author

A rare genetic variant in the cleavage site of prepro-orexin is associated with idiopathic hypersomnia.

NPJ genomic medicine·2022
Same author

Paradoxical changes in mood-related behaviors on continuous social isolation after weaning.

Experimental brain research·2021
Same author

A variant at 9q34.11 is associated with HLA-DQB1*06:02 negative essential hypersomnia.

Journal of human genetics·2018

Related Experiment Video

Updated: Feb 26, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K

Prolonged QTc Interval Normalization After Switch to Lurasidone: A Case Series.

Daisuke Takeuchi1, Naoto Omata1,2, Junichi Murayama1

  • 1Department of Psychiatry, Fukui Hospital.

Journal of Clinical Psychopharmacology
|February 25, 2026
PubMed
Summary

Switching to lurasidone, an atypical antipsychotic, effectively reduced QTc prolongation in patients previously treated with other psychiatric medications. This suggests lurasidone may lower the risk of sudden cardiac death in psychiatric patients.

Keywords:
ECGQTc prolongationantidepressantsantipsychoticslurasidone

More Related Videos

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.4K
Electrocardiogram Recordings in Anesthetized Mice using Lead II
04:16

Electrocardiogram Recordings in Anesthetized Mice using Lead II

Published on: June 20, 2020

14.4K

Related Experiment Videos

Last Updated: Feb 26, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.4K
Electrocardiogram Recordings in Anesthetized Mice using Lead II
04:16

Electrocardiogram Recordings in Anesthetized Mice using Lead II

Published on: June 20, 2020

14.4K

Area of Science:

  • Cardiology
  • Psychiatry
  • Pharmacology

Background:

  • QTc prolongation is a serious side effect of antipsychotics and antidepressants, potentially leading to fatal arrhythmias like torsade de pointes.
  • Lurasidone, an atypical antipsychotic, has a low incidence of QTc prolongation.
  • The impact of switching to lurasidone in patients with existing QTc prolongation is not well-documented.

Purpose of the Study:

  • To investigate the effect of switching to lurasidone on QTc intervals in patients experiencing QTc prolongation due to other antipsychotics or antidepressants.

Main Methods:

  • A case series included nine inpatients with QTc prolongation.
  • QTc intervals were measured before and after the switch to lurasidone.

Main Results:

  • The majority of patients showed a reduction in QTc intervals after switching to lurasidone.
  • This indicates a potential benefit of lurasidone in managing QTc prolongation.

Conclusions:

  • Switching to lurasidone can effectively reduce QTc prolongation induced by other psychiatric medications.
  • Lurasidone may decrease the risk of sudden cardiac death in psychiatric patients by shortening QTc intervals.